311 €€249/year-20%

Clinical research

Clinical trials and publications.

Evidence behind the NostraAI model in inflammatory bowel disease and supportive oncology care. Read the publications, not just the headlines.

4

scientific publications

1.200+

participants in clinical trials reported by NostraBiome

>70%

greatly improved at three months in the refractory IBD study

The total number of participants is not the sum of the samples of the four papers; cohorts may overlap.

01 · Adult inflammatory bowel disease · Biomedicine · 2025

A novel personalized microbiome-based treatment for inflammatory bowel disease

NostraBiome internal validation study results

Population and design

Patients with inflammatory bowel disease; internal validation study.

What was studied

Personalized microbiome modulation based on microbiome and clinical data evaluated for symptom control and remission outcomes.

Results reported

Improvements in symptoms and measures of remission are described. Definitions and analysis should be read in the full publication.

Read the study · DOI:10.3390/biomedicines13040795

02 · Inflammatory bowel disease in children · Microorganisms · 2025

Tailored microbiome modulation for better clinical outcomes in pediatric inflammatory bowel disease

A multi-omics and interventional approach

Population and design

Children with inflammatory bowel disease.

What was studied

Multi-omics analysis (metagenomics, metabolomics, transcriptomics and clinical biomarkers) for microbiome targeted interventions.

Results reported

The study examines dysbiosis, intervention targets and clinical response in pediatric IBD. The findings do not extend to all childhood digestive conditions.

Read the study · DOI:10.3390/microorganisms13051047

03 · Refractory inflammatory bowel disease · International Journal of Molecular Sciences

AI-guided multi-omic modulation of the microbiome improves clinical and inflammatory outcomes in refractory IBD

A real world study

Population and design

358 adults with treatment-refractory inflammatory bowel disease · three-month program.

What was studied

Stool metagenomics, blood biomarkers, micronutrients and clinical data informed individual microbiome modulation and diet plans.

Results reported

Over 70% described their general condition as "much improved" at three months; hs-CRP and faecal calprotectin decreased in more than 85% of patients (proportion of those with a decrease, not an 85% decrease).

Read the study · DOI:10.3390/ijms27010201

04 · Supportive cancer care · Cancers

AI-guided personalized gut microbiome modulation for persistent gastrointestinal symptoms in oncology patients

Clinical efficacy and biological correlates in a prospective validation study

Population and design

Oncology patients with persistent secondary gastrointestinal symptoms; prospective study.

What was studied

Microbiome, clinical and laboratory data informed personalized dietary and supplement recommendations over the course of three months.

Results reported

Better transit and energy are described, with changes in beneficial bacteria and metabolic markers. It is supportive research, not proof of cancer treatment.

Read the study · DOI:10.3390/cancers18091453

What these studies can and cannot say

Real-world and internal validation studies show promising clinical signals. Without a randomized comparison group, the changes cannot be attributed to the intervention alone, and the results do not isolate the effect of the AI ​​or a single supplement. Findings from IBD or oncology do not automatically extend to other conditions.

Medical device and clinical evidence

NostraBiome describes its software as CE marked according to EU MDR 2017/745, with ISO 13485 quality management and EUDAMED registration. CE marking is a state of conformity, not a guarantee of benefit for every use. Diagnosis and treatment remain the physician's decision.